Passage Bio rises on positive early-stage data for dementia treatment

Passage Bio

20/12/2023 12:34

** Shares of therapy developer Passage Bio  PASG.O  rise
~17% to 88 cents premarket
    ** Co says its early-stage trial for patients with a type of
frontotemporal dementia (FTD) showed sustained elevated
progranulin levels up to six months post-treatment
    ** Progranulin is a type of protein whose deficiency can
lead to FTD
    ** FTD is an uncommon type of dementia that causes problems
with behaviour and language
    ** Up to last close, stock down 45% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))